Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2016 (2016), Article ID 3162595, 11 pages
http://dx.doi.org/10.1155/2016/3162595
Clinical Study

A Comparison of Short- and Long-Term Therapeutic Outcomes of Infliximab- versus Tacrolimus-Based Strategies for Steroid-Refractory Ulcerative Colitis

Division of Gastroenterology, Tohoku University Graduate School of Medicine, 1-1 Seiryo, Aoba-ku, Sendai 980-8574, Japan

Received 2 October 2015; Revised 24 December 2015; Accepted 3 January 2016

Academic Editor: Per Hellström

Copyright © 2016 Katsuya Endo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. C. Truelove and L. J. Witts, “Cortisone in ulcerative colitis; final report on a therapeutic trial.,” British Medical Journal, vol. 2, no. 4947, pp. 1041–1048, 1955. View at Publisher · View at Google Scholar · View at Scopus
  2. J. H. Baron, A. M. Connell, T. G. Kanaghinis, J. E. Lennard-Jones, and A. F. Jones, “Out-patient treatment of ulcerative colitis. Comparison between three doses of oral prednisone,” British Medical Journal, vol. 2, no. 5302, pp. 441–443, 1962. View at Publisher · View at Google Scholar · View at Scopus
  3. S. C. Truelove and D. P. Jewell, “Intensive intravenous regimen for severe attacks of ulcerative colitis,” The Lancet, vol. 303, no. 7866, pp. 1067–1070, 1974. View at Publisher · View at Google Scholar · View at Scopus
  4. W. A. Faubion Jr., E. V. Loftus Jr., W. S. Harmsen, A. R. Zinsmeister, and W. J. Sandborn, “The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study,” Gastroenterology, vol. 121, no. 2, pp. 255–260, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. G.-T. Ho, P. Chiam, H. Drummond, J. Loane, I. D. R. Arnott, and J. Satsangi, “The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort,” Alimentary Pharmacology and Therapeutics, vol. 24, no. 2, pp. 319–330, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. J. P. Gisbert, P. Niño, C. Cara, and L. Rodrigo, “Comparative effectiveness of azathioprine in Crohn's disease and ulcerative colitis: prospective, long-term, follow-up study of 394 patients,” Alimentary Pharmacology and Therapeutics, vol. 28, no. 2, pp. 228–238, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. J. P. Gisbert, P. M. Linares, A. G. McNicholl, J. Maté, and F. Gomollón, “Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis,” Alimentary Pharmacology & Therapeutics, vol. 30, no. 2, pp. 126–137, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. K. J. Khan, M. C. Dubinsky, A. C. Ford, T. A. Ullman, N. J. Talley, and P. Moayyedi, “Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis,” The American Journal of Gastroenterology, vol. 106, no. 4, pp. 630–642, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. P. Rutgeerts, W. J. Sandborn, B. G. Feagan et al., “Infliximab for induction and maintenance therapy for ulcerative colitis,” The New England Journal of Medicine, vol. 353, no. 23, pp. 2462–2476, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Järnerot, E. Hertervig, I. Friis-Liby et al., “Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study,” Gastroenterology, vol. 128, no. 7, pp. 1805–1811, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. W. Reinisch, W. J. Sandborn, D. W. Hommes et al., “Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial,” Gut, vol. 60, no. 6, pp. 780–787, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. W. J. Sandborn, G. van Assche, W. Reinisch et al., “Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis,” Gastroenterology, vol. 142, no. 2, pp. 257.e3–265.e3, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Lichtiger, D. H. Present, A. Kornbluth et al., “Cyclosporine in severe ulcerative colitis refractory to steroid therapy,” The New England Journal of Medicine, vol. 330, no. 26, pp. 1841–1845, 1994. View at Publisher · View at Google Scholar · View at Scopus
  14. G. D'Haens, L. Lemmens, K. Geboes et al., “Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis,” Gastroenterology, vol. 120, no. 6, pp. 1323–1329, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. H. Ogata, T. Matsui, M. Nakamura et al., “A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis,” Gut, vol. 55, no. 9, pp. 1255–1262, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. D. C. Baumgart, J. P. Pintoffl, A. Sturm, B. Wiedenmann, and A. U. Dignass, “Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease—a long-term follow-up,” The American Journal of Gastroenterology, vol. 101, no. 5, pp. 1048–1056, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. D. Laharie, A. Bourreille, J. Branche et al., “Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial,” The Lancet, vol. 380, no. 9857, pp. 1909–1915, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Croft, A. Walsh, J. Doecke, R. Cooley, M. Howlett, and G. Radford-Smith, “Outcomes of salvage therapy for steroid-refractory acute severe ulcerative colitis: ciclosporin vs. infliximab,” Alimentary Pharmacology & Therapeutics, vol. 38, no. 3, pp. 294–302, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. K. H. Chang, J. P. Burke, and J. C. Coffey, “Infliximab versus cyclosporine as rescue therapy in acute severe steroid-refractory ulcerative colitis: a systematic review and meta-analysis,” International Journal of Colorectal Disease, vol. 28, no. 3, pp. 287–293, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. J. E. Naves, J. Llaó, A. Ruiz-Cerulla et al., “Long-term comparative efficacy of cyclosporine- or infliximab-based strategies for the management of steroid-refractory ulcerative colitis attacks,” Inflammatory Bowel Diseases, vol. 20, no. 8, pp. 1375–1381, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Fellermann, Z. Tanko, K. R. Herrlinger et al., “Response of refractory colitis to intravenous or oral tacrolimus (FK506),” Inflammatory Bowel Diseases, vol. 8, no. 5, pp. 317–324, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Benson, T. Barrett, M. Sparberg, and A. L. Buchman, “Efficacy and safety of tacrolimus in refractory ulcerative colitis and Crohn's disease: a single-center experience,” Inflammatory Bowel Diseases, vol. 14, no. 1, pp. 7–12, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. K. J. Schmidt, K. R. Herrlinger, J. Emmrich et al., “Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis—experience in 130 patients,” Alimentary Pharmacology & Therapeutics, vol. 37, no. 1, pp. 129–136, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Yamamoto, H. Nakase, S. Mikami et al., “Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis,” Alimentary Pharmacology & Therapeutics, vol. 28, no. 5, pp. 589–597, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Yamamoto, H. Nakase, M. Matsuura, S. Masuda, K.-I. Inui, and T. Chiba, “Tacrolimus therapy as an alternative to thiopurines for maintaining remission in patients with refractory ulcerative colitis,” Journal of Clinical Gastroenterology, vol. 45, no. 6, pp. 526–530, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. D. Rachmilewitz, F. Barbier, P. Defrance et al., “Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial,” British Medical Journal, vol. 298, no. 6666, pp. 82–86, 1989. View at Publisher · View at Google Scholar · View at Scopus
  27. R. Panaccione, S. Ghosh, S. Middleton et al., “Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis,” Gastroenterology, vol. 146, no. 2, pp. 392–400.e3, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Armuzzi, D. Pugliese, S. Danese et al., “Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis,” Inflammatory Bowel Diseases, vol. 20, no. 8, pp. 1368–1374, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. P. Deepak, H. Sifuentes, M. Sherid, D. Stobaugh, Y. Sadozai, and E. D. Ehrenpreis, “T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study,” The American Journal of Gastroenterology, vol. 108, no. 1, pp. 99–105, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. N. Issa, A. Kukla, and H. N. Ibrahim, “Calcineurin inhibitor nephrotoxicity: a review and perspective of the evidence,” American Journal of Nephrology, vol. 37, no. 6, pp. 602–612, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. M. F. Neurath and S. P. L. Travis, “Mucosal healing in inflammatory bowel diseases: a systematic review,” Gut, vol. 61, no. 11, pp. 1619–1635, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Naganuma, T. Fujii, and M. Watanabe, “The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease,” Journal of Gastroenterology, vol. 46, no. 2, pp. 129–137, 2011. View at Publisher · View at Google Scholar · View at Scopus